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Abstract: Sterilisation and preservation of vesicle formulations are important considerations for
their viable manufacture for industry applications, particular those intended for medicinal use.
Here, we undertake an initial investigation of the stability of hybrid lipid-block copolymer
vesicles to common sterilisation and preservation processes, with particular interest in how
the block copolymer component might tune vesicle stability. We investigate two sizes
of polybutadiene-block-poly(ethylene oxide) polymers (PBd12-PEO11 and PBd22-PEO14) mixed
with the phospholipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) considering the
encapsulation stability of a fluorescent cargo and the colloidal stability of vesicle size distributions.
We find that autoclaving and lyophilisation cause complete loss of encapsulation stability under the
conditions studied here. Filtering through 200 nm pores appears to be viable for sterilisation for
all vesicle compositions with comparatively low release of encapsulated cargo, even for vesicle size
distributions which extend beyond the 200 nm filter pore size. Freeze-thaw of vesicles also shows
promise for the preservation of hybrid vesicles with high block copolymer content. We discuss the
process stability of hybrid vesicles in terms of the complex mechanical interplay between bending
resistance, stretching elasticity and lysis strain of these membranes and propose strategies for future
work to further enhance the process stability of these vesicle formulations.
Keywords: liposomes; polymersomes; filtration; freeze-thaw; membrane mechanics; encapsulation
stability
1. Introduction
Hybrid vesicles aim to combine the properties of biomimetic liposomes and synthetic
polymersomes into composite membrane-bound capsules with broader tuneability of material
properties [1–10]. This expanded material parameter space is anticipated to be beneficial in the
development of hollow vesicle structures for technological applications such as sensors, biotechnology,
nanoreactors, synthetic biology and formulated products, including those intended for medicinal
purposes [11–21].
Individually, liposomes and polymersomes offer different advantages [22]. Liposomes, composed
of natural lipids, form bilayer membranes that closely mimic the structural matrix of native
biomembranes. This makes them highly biocompatible and provides a native-like environment
if integral membrane proteins are desired to add functionality to the membrane [23–27]. However,
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liposomes can have inherent instabilities. Their membranes are highly flexible under bending
deformations, but weak under stretching deformations, with a lysis strain of less than 5% [28,29].
The labile fluidity of the membrane can lead to transient membrane defects that frustrates long term
encapsulation stability and lipid peroxidation can cause chemical instabilities in these structures.
Polymersomes, due to their synthetic nature, are often less biocompatible than their lipid
counterparts but offer greater mechanical stability and a broader chemical parameter space [30].
Amphiphilic copolymers that form vesicles can have several different architectures, the most common
being AB diblock (A = hydrophilic, B = hydrophobic) [6], ABA [31] and ABC tri-block polymers [32]
where A and C are chemically different hydrophilic blocks and finally graft copolymers [33].
Formation of polymersomes depends on the amphiphilic co-polymers molecular weight, polydispersity
and hydrophilic/hydrophobic block lengths ratio, which is ideally less than 1:3 to form vesicular
structures [34]. Their membranes are often thicker than liposome membranes, which provides greater
bending resistance and their enhanced elasticity under stretching makes them tough and durable [22].
The polymer chemistry can be designed to minimise chemical instability but also to incorporate novel
functionality. In blending liposomes and polymersomes to create hybrid vesicles, the ambition is to
combine advantageous properties of these materials while off-setting their weaknesses [35].
For medicinal applications in particular, stringent regulatory requirements exist for the sterilisation
and preservation during the transportation and storage of these formulations [36]. Vesicles need to
exhibit good stability under appropriate processing conditions that maintain the encapsulation of
active compounds and the colloidal stability of vesicle structures.
Sterilisation is required to make the product safe for public use. It is the process by which all
forms of life are destroyed, removed or permanently inactivated. Instead of an absolute measure of
sterilisation, pharmaceutical industries use processes that reduce the probability of the survival of
undesired organisms to a negligible level. Currently, pharmaceutical companies use thermal, filtration
and irradiation techniques to sterilise their products [36,37]. Thermal sterilisation (Figure 1a), by
using an autoclave, is the most common and the most reliable technique as it achieves destruction of
microorganisms by irreversible denaturation of enzymes [36] and it allows the sterilisation of larger
objects more easily than filtration [38].
Polymers 2020, 12, x 17 of 17 
 
deformations, but weak under stretching deformations, with a lysis strain of less than 5% [28,29]. The 
labile fluidity of the membrane can lead to transient membrane defects that frustrates long term 
encapsulation stability and lipid peroxidation can cause chemical instabilities in these structures.  
Polymersomes, due to their synthetic nature, are often less biocompatible than their lipid 
counterparts but offer greater mechanical stability and a broader chemical parameter space [30]. 
Amphiphilic copolymers that form vesicles can have several different architectures, the most 
common being AB diblock (A = hydrophilic, B = hydrophobic) [6], ABA [31] and ABC tri-block 
polymers [32] where A and C are chemically different hydrophilic blocks and finally graft copolymers 
[33]. Formation of polymersomes depends on the amphiphilic co-polymers molecular weight, 
polydispersity and hydrophilic/hydrophobic block lengths ratio, which is ideally less than 1:3 to form 
vesicular structures [34]. Their membranes are often thicker than liposome membranes, which 
provides greater bending resistance and their enhanced elasticity under stretching makes them tough 
and durable [22]. The polymer chemistry can be designed to minimise chemical instability but also 
to incorporate novel functionality. In blending liposomes and polymersomes to create hybrid 
vesicles, the ambition is to combine advantageous properties of these materials while off-setting their 
weaknesses [35]. 
For medicinal applications in particular, stringent regulatory requirements exist for the 
sterilisation and preservation during the transportation and storage of these formulations [36]. 
Vesicles need to exhibit good stability under appropriate processing conditions that maintain the 
encapsulation of active compounds and the colloidal stability of vesicle structures. 
Sterilisation is required to make the product safe for public use. It is the process by which all 
forms of life are destroyed, removed or permanently inactivated. Instead of an absolute measure of 
sterilisation, pharmaceutical industries use processes that reduce the probability of the survival of 
undesired organisms to a negligible level. Currently, pharmaceutical companies use thermal, 
filtration and irradiation techniques to sterilise their products [36,37]. Thermal sterilisation (Figure 
1a), by using an autoclave, is the most common and the most reliable technique as it achieves 
destruction of microorganisms by irreversible denaturation of enzymes [36] and it allows the 
sterilisation of larger objects more easily than filtration [38]. 
 
Figure 1. Schematic of sterilisation and preservation processes applied to vesicle formulations. (a) 
Autoclaving; (b) filtration; (c) freeze-thaw and lyophilisation. 
Filtration through a maximum of a 0.22 µm membrane is usually used for sterilisation of 
thermally labile solutions, while sterilisation of active ingredients or medical devices can be achieved 
by irradiation [37]. Filtration exerts fluid shear stresses on vesicles as they pass down channels in the 
Figure 1. Schematic of sterilisation and preservation processes applied to vesicle formulations.
(a) Autoclaving; (b) filtration; (c) freeze-thaw and lyophilisation.
Polymers 2020, 12, 914 3 of 17
Filtration through a maximum of a 0.22 µm membrane is usually used for sterilisation of thermally
labile solutions, while sterilisation of active ingredients or medical devices can be achieved by
irradiation [37]. Filtration exerts fluid shear stresses on vesicles as they pass down channels in the filter
membrane (Figure 1b). While vesicles smaller than the filter pore size might fit within the channel
without needing to deform, under flow, the Poiseuille velocity flow field in the channel indicates the
fluid is moving much faster in the centre of the pore channel than at the edges. This will deform
even small vesicles and, depending on the magnitude of these stresses, could induce transient pore
formation in the membrane, compromising encapsulation stability, or even causing break-up of the
vesicles. For larger vesicles, greater in size than the pore diameter, these vesicles must also deform at
the entrance to the channel and will experience greater shear stresses that increases the probability that
these vesicles might break-up into smaller structures.
Stability during the storage and transportation of vesicle formulations can also be a challenge.
This may be in the transport between primary and secondary manufacturing sites or between the
manufacturer and end-user. Once reaching the end-user, formulations may be stored for some time
before their final use. Cold chain transportation is frequently used for medicinal products to maintain
the stability and activity of their ingredients. Cryogenic conditions are frequently used for preservation
during the transportation and storage of delicate biologics and labile formulations.
Liquid formulations are often frozen for preservation (Figure 1c). However, storing frozen samples
for an extended period can cause ice crystal formation that could cause membrane damage for vesicles
during freezing and thawing [39]. Besides potential damage from ice crystals, vesicles will become
stressed by the expansion of water inside their lumen upon freezing. The volume of water expands by
~9% upon freezing, which will exert a ~6% areal strain on the confining membrane, which exceeds the
lysis strain for lipid membranes. Indeed, freeze-thaw cycles are used to intentionally rupture liposomes
during the passive loading of compounds from the bulk medium. Formulations may experience several
freeze-thaw processes during manufacture, transport and storage, whether deliberate or unintentional.
Fluctuations in temperature during transport from improper storage and shipping can cause some
samples to reach their destination past their shelf life. This makes some drug formulations ineffective
or even harmful [40,41].
Lyophilisation (freeze-drying) can also be used to maintain the stability of lipids during
transportation and storage. During the freeze-drying process the product is frozen, thus immobilising
the sample and allowing it to retain its original form, and then the water is removed by sublimation
(Figure 1c), preventing microbial growth [42]. For lipids, the absence of water would minimise the rate
of hydrolysis during storage [43]. However lyophilisation of liposome formulations is challenging to
maintain encapsulation and structural stability. Additives are required for liposome cryopreservation,
yet their efficacy can be variable and inconsistent [44].
Here, we investigate hybrid vesicles composed of a phospholipid 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and one of two amphiphilic polybutadiene- block-polyethylene oxide
(PBd-b-PEO) diblock copolymers of different molecular weights under conditions designed to mimic
industrial sterilisation and storage/transportation processes. We explore the full hybrid compositional
space from pure lipid to pure polymer vesicles. Sterilisation is mimicked through autoclaving or
multiple filtration passes through a filter with a 0.2 µm pore size. The storage/transportation of samples
is emulated through either lyophilisation and rehydration, or multiple freeze-thaw-vortex (FTV) cycles.
This preliminary study of hybrid vesicle stability under these conditions is designed as a stringent
test of their stability that will highlight advantages that can be gained through the composition of the
hybrid formulation and to uncover aspects of these formulations that will require optimisation for
future commercial translation. As such, we investigate the hybrid vesicle in a physiological saline
buffer without additional additives for enhanced stability, such as potential cryo-preservatives.
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2. Materials and Methods
2.1. Materials
The di-block copolymers poly(1,2-butadiene)-block-(polyethylene oxide) (PBd-b-PEO) with total
molecular weights of 1800 gmol−1 and 1150 gmol−1 were purchased from Polymer Source, Inc.
(Montreal, Canada). PBd22-PEO14 (PDI 1.01) has a hydrophobic PBd block of 1200 gmol−1 (>85%
1,2 addition) and a hydrophilic PEO block of 600 gmol−1 while polybutadiene-block-poly(ethylene
oxide) (PBd12-PEO11) (PDI 1.09) purchased from Polymer Source (Dorval, Montreal, Canada) has a
hydrophobic PBd block of 650 gmol−1 (85% 1,2 addition) and a hydrophilic PEO block of 500 gmol−1.
The lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased from Avanti
Polar Lipids (Alabaster, AL, USA). 5(6)-carboxyfluorescein (CF) and other reagents were purchased
from Sigma Aldrich (St. Louis, MO, USA).
2.2. Vesicle Preparation
Large unilamellar vesicles (LUVs) were prepared by the thin film rehydration and extrusion
method. To generate different hybrid vesicle compositions, relative volumes of POPC (32 mM)
and PBd-PEO (6.57 mM) in chloroform were measured using a Hamilton syringe into a glass vial.
The solutions were dried in a vacuum desiccator to give a lipid/polymer film and then rehydrated with
1.0 mL of aqueous solution of 60 mM CF with 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) and 20 mM sodium chloride, adjusted the pH to 7.4 by dropwise addition of sodium
hydroxide. The films were incubated at 50 ◦C for 5 min and vortexed for 1 min. The suspensions were
then frozen in liquid nitrogen, thawed in a 60 ◦C water bath and vortexed for 10 s. This cycle was
repeated 5 times. Suspensions were extruded 11 times though a 100 or 400 nm pore size polycarbonate
membrane filters using a LiposoFast Basic Extruder. The nanovesicle samples were run on a Sephadex
G50 column under gravity using 40 mM HEPES and 20 mM sodium chloride buffered to pH 7.4 as
the mobile phase to remove unencapsulated CF dye. The resulting 3 mL fractions were characterised
using dynamic light scattering (DLS) for particle size distribution to confirm the presence of vesicles.
The hybrid vesicles are then further analysed for stability under sterilisation and preservation processes.
2.3. CF Release Assay
The 100 nm sized hybrid vesicle samples were split into 4 fractions of 500 µL (~2 mM). Fraction 1
was thermally sterilised using an autoclave at 121 ◦C for 15 min. Fraction 2 was lyophilised using a
VirTis Benchtop Pro Lyophiliser (Wolf Laboratories Ltd., York, UK) for 24 h after freezing the sample in
nitrogen. Fraction 3 underwent 5 filtration cycles through a 13 mm PTFE 200 nm syringe filter device
(Fisher Scientific Ltd., Hampton, NH, USA) with polypropylene housing. Fraction 4 was frozen in
liquid nitrogen, thawed in a water bath at 60 ◦C and vortexed for 3 s. The samples undergo 4 of these
freeze-thaw-vortex (FTV) cycles.
The 400 nm sized vesicles were filtered through a 13 mm PTFE 200 nm syringe filter device (Fisher
Scientific Ltd., Hampton, NH, USA) with a polypropylene housing 5 times.
CF is self-quenching at high concentrations (>40 mM) [45,46], so the emission intensity at this
concentration was often very low. The CF was encapsulated at 60 mM, so the control samples would
have a low emission intensity. When the vesicles release the encapsulated CF, the CF was diluted by
the external buffer and the fluorescence intensity increased.
To measure the CF release, 0.5 mL fractions were diluted to 2 mL (~18 µM) and the fluorescence
emission at 519 nm of CF-encapsulated vesicles was measured with excitation set to 492 nm using a
Horiba Scientific FluoroMax Plus (Horiba Ltd., Kyoto, Japan). Measurements were made on initial
vesicle fractions and between every processing cycle for each fraction. The initial vesicle preparations
were ruptured with 50 µL of 10% (w/v) Triton X-100 (end concentration 0.91% (w/v)) (Scientific
Laboratory Supplies Ltd., Nottingham, UK) to completely destabilise the vesicles and release the
encapsulated CF before a final fluorescence emission at 519 nm was measured.
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where I0 is the initial intensity of the sample, Ii is the intensity of the sample after each processing cycle
(from autoclaving, lyophilisation, FTV or filtering), and It is the intensity after the initial sample is
burst with Triton X-100.
2.4. Dynamic Light Scattering (DLS)
After separating hybrid vesicles with encapsulated CF from excess CF, the vesicles were
characterised using a Malvern Zetasizer Nano ZSP (Malvern Panalytical Ltd., Malvern, UK) with
scattering angle 173◦ to determine their size. Each hybrid vesicle sample (0.5 mM) was measured
at 25 ◦C by the DLS and the results from 3 independent repeats were averaged. Size distributions
were also measured after the processing steps described above to assess the colloidal stability of these
vesicle formulations under these conditions.
2.5. Cryo-Electron Microscopy (cryo-EM)
Vesicles of 50 mol% PBd22-PEO14 at 100 and 400 nm were imaged after initial preparation and
after the final freeze-thaw-vortex and filtration cycles respectively. For 100 nm vesicles, 400 mesh
2/2 µm Cu Quantifoil grids were used, while for 400 nm vesicles, 400 mesh Cu Lacey grids were used.
All the carbon-coated grids were glow discharged for 33 s at 10 mA to render the surface hydrophilic.
Samples (3 µL, ~2 mM) were placed directly onto the grid with a hold time of 40 s, using a FEI Vitrobot
mkIV, using a blotting time of 6 s and a blot force of 6. The samples were kept in closed cryo-pucks
under liquid nitrogen until required.
To image the girds, an FEI Titan KRIOS microscope (Thermofisher, Waltham, MA, USA) with an
accelerating voltage of 300 kV was used with a defocussing of 3 µm at a magnification of ×130,000 and
×26,000. The resolution for these images was 0.11 and 0.55 nm/pixel, respectively.
Quantitative analysis of the images required taking diameter measurements and observations
of all the vesicles in the grid holes of the carbon-coated copper grid using ImageJ. Histograms were
made to document the size distribution observed in the grid holes, and notes were made on the ratio
of multilamellar vesicles (MLVs) to unilamellar vesicles (ULVs).
3. Results
We investigated the stability of hybrid vesicles under conditions designed to mimic industrial
sterilisation and preservation processes. Our hybrid vesicles were composed of the lipid POPC
blended with one of two PBd-b-PEO diblock copolymers of different length: PBd22-PEO14 or
PBd12-PEO11. We explored the full compositional parameter space from pure lipid to pure polymer
vesicle compositions. Hybrid vesicles were formed by the thin film rehydration and extrusion method.
The vesicles were loaded with the hydrophilic fluorophore CF as a model encapsulated compound. We
studied the encapsulation stability through release of CF from vesicles by fluorescence spectroscopy
and the colloidal stability of the vesicle formulations from their hydrodynamic size distributions
obtained by DLS.
3.1. Autoclaving and Lyophilisation
Autoclaving and lyophilisation of hybrid vesicles would be the preferred choices for sterilisation
and preservation, if these formulations can be made to be stable under these conditions. Unfortunately,
both processes proved to be too destructive, causing vesicles to become unstable and release their
entire contents. Only vesicles composed of the pure components were investigated: 100% POPC, 100%
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PBd22-PEO14 and 100% PBd12-PEO11. As 100% CF release was observed in all cases (Figure 2a), it was
considered extremely unlikely that hybrid blends would perform any better.Polymers 2020, 12, x 17 of 17 
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Figure 2. Release of encapsulated 5(6)-carboxyfluorescein (CF) and size distributions from vesicles
follow ng autoc aving or lyophilisation. (a) Vesicl compositions 100% 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC), 100% polybutadiene-block-poly(ethylene oxide) (PBd12-PEO11)
and 100% PBd22-PEO14 were investigated following autoclaving or lyophilisation. Each measurement
was performed in triplicate and the errors data points represent mean ± s.d. The dynamic light
scattering (DLS) distributions of hydrodynamic diameters from (b) constrained regularisation method
for inverting data (CONTIN) fits size distributions and (c) the fitted autocorrelation functions. The size
distributions shown represent the average distribution from three independent repeats.
The colloidal stability of the vesicles under these conditions was similarly poor. DLS size
distributions were collected before and after autoclaving and lyophilisation (Figure 2b). The fitting
software returned errors f r all post-process samples exc pt for autoclaving of 100% liposomes. The poor
fits to the auto-correl ti n functi in these cases can be een in Figure 2c. The delayed exponential
decay sh wn in the auto-c rrelation functions is interpreted as aggregation and/or structural instabilities
of the vesicles during autoclaving or lyophilisation. The fact that the autocorrelation function does not
reach the baseline in some cases indicates the presence of larger multimicron structures that are likely
to undergo sedimentation.
Since these vesicles are unstable under autoclaving and lyophilisation, we further investigate
other potential methods of sterilisation and preservation. However, we do not conclude that these
techniques are fundamentally hopeless for use with hybrid vesicles: further development of the vesicle
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formulations would be required; for example, additional additives to the solution environment that
help protect the integrity of the vesicles undergoing these processes.
3.2. Filtration
Sterilisation can be achieved by filtrations through a membrane with a maximum pore size of
0.22 µm. Here, we use a 0.2 µm pore size membrane to filter hybrid vesicles for between one and five
cycles. Initially, we investigated hybrid vesicles between 0 and 100 mol% block copolymer content in
25 mol% increments for both PBd-b-PEO polymers. These vesicles were formed by extrusion through a
100 nm pore size membrane and encapsulated the CF dye.
All vesicle compositions only exhibited minimal contents release across five filtration cycles, with
the average contents release reaching at most 10%. Figure 3a shows filtration-induced contents release
from hybrid vesicles containing the shorter PBd12-PEO11 block copolymer. The unitary POPC and
PBd12-PEO11 vesicles exhibit very low (<5%) contents release across five filtration cycles and no vesicle
composition exceeds 10% average release. Analysis of variance shows that there is no statistically
significant (p < 0.05) difference between the different vesicle compositions studied.
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Figure 3. Release of encapsulated CF following filtration and size distributions before and after five
filtration cycles. CF release% is plotted against membrane composition for hybrid vesicles composed of
POPC and (a) PBd12-PEO11, or (b) PBd22-PEO14. Data are shown for between one and five filtration
cycles through a 0.2 µm pore size filter membrane. Each measurement was performed in triplicate
and the errors data points represent ean ± s.d. The DLS distributions of hydrodynamic diameters
of PBd12-PEO11 or PBd22-PEO14 hybrid vesicles before and after five filtration cycles: (c) CONTIN fit
size distributions; (d) the fitted autocorrelation functions. The size distributions shown represent the
average distribution from three independent repeats. The line at 0.2 µm denotes the filtration pore size.
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Perhaps surprisingly, the largest contents release occurred in vesicles composed of the larger
PBd22-PEO14 block copolymer (Figure 3b), where a priori expectations might be that these would be
the most mechanically stable vesicles. The only statistically significant difference in contents release
is for pure PBd22-PEO14 polymersomes, which is significant when compared to all other membrane
compositions, where the extent of release marginally exceeds 10% for the fourth and fifth filtration
cycle. However, this contents release is still relatively low, even after several filtration cycles.
Hybrid vesicles (100 nm extrusion pore size) also demonstrate colloidal stability following multiple
filtration cycles (Figure 3c,d and Tables S1–S4). Vesicle size distributions obtained by DLS before
and after five filtration cycles were comparable for all hybrid vesicle compositions and both polymer
sizes. No evidence of break-up or aggregation of vesicles was observed. The red line on these graphs
denotes the filter pore size of 200 nm. Vesicles with higher polymer content exhibit a tail in their size
distribution which stretches beyond the filtration pore size. While these vesicles can pass the filter
without notable changes in the particle size distribution, these also largely correlate with the vesicle
compositions that exhibit the highest contents release, suggesting that the probability of transient
pores forming in the vesicle membrane increases when vesicles are larger than the pore size and must
significantly deform during the transit of the pore channel. This is particularly notable for the size
distribution of 100 mol% PBd22-PEO14 vesicles, where the highest contents release was measured in
Figure 3b.
Given that most of the 100 nm extruded vesicles are smaller than the 200 nm filter size, we
presented a more stringent test of hybrid vesicle stability under filtration by using 400 nm extruded
vesicles. In this series of experiments, we investigated the pure lipid and polymer vesicles as well as
the 50 mol% hybrid compositions by both polymer sizes.
Contents release from 400 nm extruded vesicles was significantly greater than previously observed
for 100 nm extruded vesicles (Figure 4). While the shorter PBd12-PEO11 polymer appears to provide a
mildly protective effect in hybrid vesicles with a gentle reduction in CF release observed with increasing
polymer composition, these differences are not statistically significant (Figure 4a). The only statistically
significant difference in contents release is again observed for pure PBd22-PEO14 polymer vesicles,
which show reduced encapsulation stability compared to the POPC liposomes and 50 mol% hybrid
vesicles (Figure 4b). Despite this, overall contents release after five filtration cycles is small, being
less than 15% for all compositions except the 100 mol% PBd22-PEO14 vesicles, where contents release
exceeds 25% after five filter passes.
The filtration of PBd22-PEO14 vesicles was more difficult than other vesicle compositions, requiring
much higher pressures to be applied to force the vesicle sample through the filter. This indicates that
these vesicles are the most rigid due to the high bending stiffness of the thicker polymer membranes.
The higher pressures that need to be applied during filtration are therefore the likely cause of the
enhanced contents release from these vesicles. On the other hand, the shorter polymer has lower
bending resistance, allowing these vesicles to more easily pass through the filter and may impart some
enhanced elasticity to hybrid vesicles, giving a mild protective effect to hybrid vesicles under filtration.
All vesicles were much smaller in size than the 400 nm pore size of the extrusion membrane for
vesicle preparation (Figure 4c,d and Tables S5–S8). However, a significant proportion of vesicles are
larger than the 200 nm filter size, meaning that they would need to significantly deform or break-up to
pass through the filter. The initial 100% PBd22-PEO14 vesicle size distribution also showed a bimodal
distribution with peaks at 108 and 519 nm. Following five filter passes, all pure component vesicles,
whether lipid or polymer, showed multimodal size distributions with larger structures present in
solution that are indicative of aggregation and loss of colloidal stability in these samples.
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Figure 4. Release of encapsulated CF from 400 nm hybrid vesicles following filtration and size
distributions before and after five filtration cycles. CF release% is plotted against membrane composition
for hybrid vesicles composed of POPC and (a) PBd12-PEO11, or (b) PBd22-PEO14. Data are shown for
between one and five filtration cycles through a 0.2 µm pore size filter membrane. Each measurement
was performed in triplicate and the errors data points represent mean ± s.d. The DLS distributions of
hydrodynamic diameters of PBd12-PEO11 or PBd22-PEO14 hybrid vesicles before and after five filtration
cycles: (c) CONTIN fit size distributions; (d) the fitted autocorrelation functions. The size distributions
shown represent the average distribution from three independent repeats. The line at 0.2 µm denotes
the filtration pore size.
Interestingly, both 50% hybrid vesicle formulations fared best under filtration with comparable
monomodal size distributions before and after filtration. This enhanced colloi al stability might be
du to he synergistica ly enhanced properties of the blended lipid-p lymer hybrid membranes.
However, it is also plausible that this is sim ly due to the smaller initial size distribu ion of
these hybrid vesicles (145 nm for 50/50 mol% POPC/PBd12-PEO11 hybrid vesicles and 182 nm
for 50/50 mol% POPC/PBd22-PEO14 h brid vesicles). We previ usly observed good colloidal stability
for 100 nm extrusion membrane v sicle formulati ns, therefore this latter xpl ation seems most likely.
T is smaller initi l siz distribution of 50 mol% hybrid vesicles might be du to a r ferred curvature
o the hybrid v si le membrane that limits the maximum siz of vesicles that form at this composi ion.
We further investigated the 400 nm 50/50 mol% POPC/PBd22-PEO14 hybrid vesicles before and
after filtration by cryo-electron microscopy (cryo-EM) (Figure 5). For c yo-EM, an aqueous sample
is placed on a carbon-c ated copper g id which is plun ed in liquid ethan that vitrifies the wat
into a glass-like state to enable the sample to be seen [47,48]. Ice thickness can vary depending on the
dimensions of the particle but usually ranges from a few nanometres to a hundred nanometres [48].
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The thicker the ice (>100 nm), the worse the resolution [49]. On the other hand, if the ice is too thin, then
either the sample is pushed towards the edge of the grid holes, or the sample can have a high affinity
for the carbon support, leaving the grid hole empty of sample and causing particle aggregation [47].
Variations in ice thickness can also sort the vesicles by size, concentrating the larger vesicles in thicker
ice [50]. Lacey carbon-coated grids have a higher percentage of open area which allows larger particles
to protrude over the edges of the grid holes, and therefore be seen at a higher resolution [51].
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Figure 5. Cryo-transmission electron microscopy (Cryo-TE ) of 50 mol% PBd -PEO14 hybrid vesicle
(400 nm extrusion me brane) before and after five filtration cycles. (a) Histogram of initial vesicle
sizes from cryo-TE i ages; (b) representation i ages of vesicles before filtration; (c) histogram of
vesicle sizes after filtration from cryo-TEM images; (d) representation images of vesicles after filtration.
Scale bars represent 100 nm.
Initial 50 mol% PBd22-PEO14 hybrid vesicles were found to have an average diameter of
113 ± 95 nm and 32% of vesicles were observed to be multilamellar. This compares favourably
with the previous DLS analysis where these vesicles have a z-average of 124 nm (PDI 0.279). However,
following filtration, the cryo-EM analysis gave an average vesicle size of 57 ± 32 nm with 7% of
vesicles found to be multilamellar. This differs from our DLS analysis, which showed a post-filtration
z-average of 120 nm (PDI 0.269). The reduction in average size observed in cryo-EM can be seen from
the histograms to be due to the removal of larger >200 nm vesicles from the post-filtered samples, likely
due to vesicle break-up. Vesicle break-up during filtration would also explain the lower proportion of
multilamellar vesicles that we observe. While larger vesicles can often be excluded from the thin ice
in the holes of the EM grid, artificially leading to smaller size distributions by cryo-EM compared to
DLS, the comparison between the pre- and post- filtered hybrid vesicles by cryo-EM would appear to
be significant. The break-up of some larger and multilamellar vesicles during filtration would likely
account for the ~15% leakage of vesicle contents observed in Figure 4.
3.3. Freeze-Thaw-Vortex
An alternative preservation process to lyophilisation is to store vesicle samples frozen from the
liquid state without sublimation of excess water. Therefore, we investigate the stability of vesicles
to up to four freeze-thaw-vortex (FTV) cycles. The vortexing step following the thawing of frozen
samples is included to ensure the vesicles are fully resuspended in the liquid state.
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Liposome encapsulation was observed to be highly unstable even after a single FTV cycle (Figure 6).
This is unsurprising as freeze-thaw cycles are frequently used for passive loading of cargo in liposome
preparation protocols, as this renders the membrane temporarily permeable. Conversely, 100% polymer
vesicles exhibit much greater encapsulation stability across four FTV cycles with hybrid formulations
showing increasing stability with increasing block copolymer composition in the membranes. For all
vesicle compositions, CF release increased after each FTV cycle.
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Figure 6. Release of encapsulated CF from 100 nm hybrid vesicles following freeze-thaw-vortex (FTV)
cycles and size distributions before and after four FTV cycles. CF release% is plotted against membrane
composition for hybrid vesicles composed of POPC and (a) PBd12-PEO11, or (b) PBd22-PEO14. Data
are shown for between one and four FTV cycles. Each measurement was performed in triplicate
and the errors data points represent mean ± s.d. The DLS distributions of hydrodynamic diameters
of PBd12-PEO11 or PBd22-PEO14 hybrid vesicles before and after four FTV cycles: (c) CONTIN fit
size distributions; (d) the fitted autocorrelation functions. The size distributions shown represent the
average distribution from three independent repeats.
Vesicles containing the larger PBd22-PEO14 polymer were also observed to have more stable CF
encapsulation than those formulated with the PBd12-PEO11 polymer. We interpret this as the thicker
membranes formed from the larger block copolymer having greater elasticity, permitting the membrane
to stretch without rupture during the volume expansion of freezing. Furthermore, the thicker, more
elastic membranes of these vesicles enhances protection from damage that might be caused by the
local growth of ice crystals in the sample.
FTV cycles had the most impact on the colloidal stability of lipid-rich vesicles. We measured the
vesicle size distributions by DLS before and after four FTV cycles (Figure 6c,d and Tables S9–S12).
While the post-FTV size distributions are mostly monomodal (with the exception of 25 mol% and
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75 mol% PBd22-PEO14 hybrid vesicles), the size distributions for 100% POPC and 25 mol% polymer
hybrid vesicles significantly broaden following four FTV cycles. In contrast, the size distributions of
hybrid vesicles with ≥50 mol% polymer content are broadly similar before and after the FTV cycles.
We further investigate the effect of freeze-thaw action on the size and morphology of 50 mol%
PBd22-PEO14 hybrid vesicles by cryo-EM. Quantitative analysis of the images shown in Figure 7
indicate that the vesicles have a similar size before and after the FTV cycles (59 ± 38 vs. 60 ± 24 nm) and
a slightly increased prevalence of multilamellar vesicles following FTV cycles (15% vs. 24%). However
the cryo-EM grid preparation appears to favour smaller vesicles being in the grid holes, while the
majority of the larger vesicles prefers to sit on the carbon-coated support as there is a large difference in
size between the DLS and cryo-EM size distributions. The DLS analysis in Figure 6c reports z-average
sizes of 108 nm (PDI 0.213) and 101 nm (PDI 0.191) before and after four FTV cycles, respectively.
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4. Discussion
For vesicles composed of the pure lipid or block copolymer components, we find that sterilisation
using an autoclave results in a loss of colloidal stability and the release of the encapsulated CF.
Autoclaving involves exposure to high temperature, which is thought to be detrimental to lipid vesicles
by causing aggregation [38,52]. The aggregation after heat sterilisation has been suggested to lead
to instability in lipid vesicles by electrolytes, causing dehydration of the hydrophilic moiety [52].
However, in a previous study, it was found that egg or saturated lipid vesicles without encapsulated
agents could be sterilised by autoclaving. When calcein or doxorubicin were encapsulated, however,
the leakage was pronounced [38].
It was expected that the poly ri i l l be ore resistan to heat exposure as polymer
membranes are believed t st than those formed by l pids alone. Polymersomes with
a brane thickness (P E37-PEO40 and PBd46-PEO26) have previously been shown to have
both encapsulation and colloidal stability to autoclave conditions, although there is a slight shift to a
smaller vesicle size distribution [28]. t e stability of the vesicles during heat sterilisation,
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it has been suggested that sugars or polyols could be used to stabilise the vesicles [52] and the drug
could be encapsulated after vesicles have been autoclaved [38].
Lyophilisation also caused complete contents release and loss of colloidal stability in both pure
lipid and pure PBd-b-PEO polymer vesicles, indicating rupture and aggregation of the vesicles.
The initial freezing step could cause damage to vesicles from piercing by the ice crystals that form
and expansion of the encapsulated aqueous volume during freezing. However, we later show that
polymer-rich vesicle compositions in particular are comparatively stable under freeze-thaw action.
Therefore, damage caused by freezing is not solely responsible for the chronic impact of lyophilisation
on these vesicles.
During the second step of lyophilisation, water is removed by sublimation. As water is
fundamentally essential to the self-assembly of amphiphiles into vesicle polymorphs, and the degree of
hydration is known to facilitate phase transitions in lyotropic assemblies, it is perhaps not surprising
that this dehydration step can cause severe structural instabilities. Here, we considered whether the
enhanced stability of block copolymers alone might be enough to increase the stability of vesicles to
lyophilisation; however, there is no evidence for this under the conditions currently tested. However, the
damaging effects of lyophilisation have been minimised for liposomes by addition of cryoprotectants to
the continuous aqueous phase. Small molecule cryoprotectants, such as glycerol or trehalose and other
carbohydrates, can significantly reduce aggregation, fusion and leakage. Cryoprotectants have been
successfully used to enhance the stability of liposomes to lyophilisation and rehydration [43]. However,
this is notoriously challenging [44], and the potential for synergistic effects from cryoprotectants in
the solution phase and block copolymers blended within hybrid vesicle membranes is a worthwhile
avenue for future investigation.
While autoclaving and lyophilisation would need further investigation of added molecular
protectants in the solvent environment to make them viable for hybrid vesicle processing, filtration
and freeze-thaw processes appeared to be more immediately viable for sterilisation and preservation.
Vesicle filtration (200 nm pore size) resulted in relatively low contents release, particularly for
vesicles formed by extrusion through a 100 nm membrane. These vesicles also showed good colloidal
stability. However, this is perhaps relatively unsurprising since the DLS size distribution suggests that
only a small proportion of vesicles are larger than the filter pore size, although hydrodynamic sheer
stresses passing through a filter pore might cause minimal destabilisation of the membrane and loss
of contents.
A more stringent test of vesicle stability under filtration was undertaken with vesicles formed by
extrusion through 400 nm membranes. Now, a large proportion of vesicles are larger than the 200 nm
filter pore size. More significant contents release is now observed (up to 25%) and there is some loss
of colloidal stability due to vesicle break-up and aggregation. Curiously, only 50 mol% PBd-b-PEO
hybrid vesicles maintained good colloidal stability, but this might be explained by the intrinsically
smaller size distribution of these hybrid vesicles when initially formed.
When comparing between different vesicle compositions, it is interesting to note that the vesicle
compositions with the highest filtration stability are perhaps initially non-intuitive. A reasonable initial
hypothesis might be that vesicles with a high proportion of the larger PBd-b-PEO block copolymer
would be more stable under filtration due to enhanced mechanical robustness from this polymer.
However the converse is the case, where the worst performing vesicle composition is 100% PBd22-PEO14.
We interpret this to be due to the higher bending rigidity of the thicker membranes of these vesicles,
offering higher resistance to deformations required to pass through the filter membrane. This is
qualitatively manifested in the higher pressures that are required to force these vesicle samples across
the filter membrane. These higher pressures likely have a more severe impact on encapsulation stability.
Conversely, the smaller PBd12-PEO11 polymer does not have a significant impact on encapsulation
stability, likely due to a similarly low bending rigidity to pure liposomes. These hybrid vesicles
formed using this smaller polymer may also have enhanced membrane elasticity, imparting improved
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toughness to these vesicles, but this is not a statistically significant observation, likely due to the
inherently low contents release that is already seen for the POPC liposomes.
Polymer-rich vesicles can also withstand several FTV cycles, making this a more viable alternative
to lyophilisation for sample preservation. Lipid-rich vesicles have poor encapsulation stability under
freeze-thaw action, but high polymer content likely enhances stability due to the increased stretching
elasticity and higher lysis strain of polymersome membranes that is critical to their enhanced material
toughness and durability. Now, membranes rich in the larger PBd22-PEO14 polymers present the
best stability profile across several FTV cycles, having greater capacity to resist damage from solvent
expansion stresses during freezing and the growth of ice crystals.
In summary, this initial investigation indicates that filtration and freeze-thaw are the most viable
routes to sterilisation and preservation of hybrid vesicles while retaining good encapsulation and
colloidal stability of these samples. A complex interplay between the bending rigidity, stretching
elasticity and lysis strain of the membrane formulation determines which vesicles are most stable
under each of these processes. While functional performance in the desired vesicle application will
primarily dictate the optimisation of the membrane composition of vesicles, enhancing essential
processing stability is a secondary consideration that cannot be completely ignored. While filtration
is sufficient to sterilise small nano-vesicle samples, formulations that use larger vesicle sizes are less
stable to this process and further efforts to develop autoclaving as a stable process for hybrid vesicles
are worthwhile. Similarly, lyophilised vesicles would be favourable for frozen liquid samples for
the preservation of vesicles for storage and transport to reduce economic costs and environmental
impact. Therefore, further efforts to enhance hybrid vesicle stability to these harsher processes are still
of significant interest. Furthermore, additional sterilisation processes might be considered, such as
ultra-high temperature (UHT) and high temperature short time (HTST) [53] processing.
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